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Abstract: Available commercial assays may yield inaccurate hepatitis C virus (HCV) geno-
type assignment in up to 10% of cases. We investigated the cost-effectiveness of re-evaluating 
HCV genotype by population sequencing, prior to choosing a direct acting antiviral (DAA) 
regimen. Between March and September 2015, HCV sequence analysis was performed in order 
to confirm commercial LiPA-HCV genotype (Versant® HCV Genotype 2.0) in patients eligible 
for treatment with DAAs. Out of 134 consecutive patients enrolled, sequencing yielded 21 
(15.7%) cases of discordant results. For three cases of wrong genotype assignment, the putative 
reduction in efficacy was gauged between 15% and 40%. Among the eight cases for whom 
G1b was assigned by commercial assays instead of G1a, potentially suboptimal treatments 
would have been prescribed. Finally, for five patients with G1 and indeterminate subtype, the 
choice of regimens would have targeted the worst option, with a remarkable increase in costs, 
as in the case of the four mixed HCV infections for whom pan-genotypic regimens would 
have been mandatory. Precise assignment of HCV genotype and subtype by sequencing may, 
therefore, be more beneficial than expected, until more potent pan-genotypic regimens are 
available for all patients.
Keywords: HCV, HCV sequence analysis, HCV genotype, direct acting antiviral, treatment costs
Introduction
Currently available genotyping methods, based on reverse hybridization with subtype-
specific primers and probes targeting the 5′-untranslated region (5′-UTR) and core regions 
(Versant® HCV Genotype 2.0 system; Siemens Healthcare Diagnostics, Milan, Italy), as 
well as real-time PCR assays based on 5′-UTR and NS5B sequencing (Abbott HCV Geno-
type II assay; Abbott Diagnostics, Lake Forest, IL, USA), accurately differentiate major 
hepatitis C virus (HCV) genotypes in the majority of cases and are widely used because 
of their technical simplicity and lower costs.1 Routine genotyping methods, however, may 
cause wrong, inaccurate, or incomplete assignment in up to 10% of cases, due to inde-
terminate results, mixed infections, wrong subtyping, and even wrong genotyping, as we 
recently reported.2 Misclassifications of HCV genotype were described in characterization 
of genotypes 5 and 6 and in subtyping of genotypes.2–6 Versant HCV Genotype 2.0 fails 
to identify genotype 1 subtype in 2.2%–7.4% of the cases.5 In particular, cause of mis-
classification was due to variability of 5′-UTR of HCV. This region is not appropriate for 
discriminating HCV strains at the subtype level and for distinguishing many genotype 6 
samples from genotype 1 as well as for distinguishing subtypes within genotypes 1, 2, and 3.6 
Incorrect assignments of genotype were associated with nucleotide polymorphisms in 
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the 5′-UTR of HCV that may alter the ability of probe/primer 
of commercial assays to recognize viral strains. Indeterminate 
genotype results were reported for changes at positions 166 
and 119 in genotype 2b and 138, 108, and 99 in genotype 3h of 
5′-UTR of HCV.7 As most of the currently available therapeutic 
options target HCV genotype 1 strains, treatment of other geno-
types, in particular genotype 3, is presently less efficient and 
more costly when directly acting antivirals (DAAs) are used.8 
Reassessment of HCV genotype and subtype by sequencing 
prior to interferon-free regimens may reduce the risk of treat-
ment failure and consequent undue pharmacological costs 
driven by inappropriate genotype characterization and may, 
therefore, turn out quite cost beneficial.2,9 We investigated the 
cost-effectiveness of re-evaluating HCV genotype by popula-
tion sequencing, prior to choosing a DAA regimen among 
currently available options, in a mono-centric Italian cohort.
Methods
Between March, 2015, and September, 2015, at the Liver and 
Infectious Diseases Units of Pescara General Hospital, Italy, 
HCV sequence analysis was performed in order to confirm 
previous commercial assignment by a second-generation 
LiPA-HCV genotype assay (Versant HCV Genotype 2.0; 
 Siemens Healthcare Diagnostics) in all consecutive can-
didates to treatment with DAAs. The local Health District 
Authority was requested to evaluate the possible benefits of 
the experimental procedure, and found it likely cost-effective 
and funded 200 consecutive assays for the purpose of this 
evaluation. Direct population sequencing was, therefore, per-
formed for both NS5A and NS3 HCV genes at the University 
of Tor Vergata (Rome) through highly efficient home-made 
protocols as previously reported.2 Expert interpretation of 
mutations and sequence variants detected was also provided 
by the same source (University of Rome Tor Vergata) for 
each patient, to help in choosing the most appropriate and 
individualized regimen. The turnaround time allowance from 
sample dispatching to availability of assay results was set at a 
maximum of 3 weeks, to avoid undue delaying of treatments. 
For the purpose of the present study, in each case of resolved 
or discordant HCV genotype and/or subtype after sequencing, 
we calculated the difference in treatment costs between the 
most likely prescription that would have been possible on the 
basis of previously available commercial HCV genotype and 
subtype only, and the most likely prescription made possible by 
the availability of sequence results with expert interpretation. 
Interferon-free regimens were prescribed by attending special-
ists in accordance with current European Association for the 
Study of the Liver Guidelines and Italian Regulatory Agency 
(AIFA) reimbursement  requirements.10,11 Sustained virologic 
response 12 (SVR-12) was defined as undetectable viral load 
at 12 weeks after treatment. Expected efficacy for each pre-
scribed regimen was derived by currently available published 
SVR-12 data for selected reference treatments. The costs 
considered in the analysis are direct medical costs (referred to 
2015) related to each prescribed drug and/or regimen, retrieved 
from the Pharmacy Unit of Pescara General Hospital, and the 
genotypic test reimbursement received by the hospital from 
the Regional Health Service (ie, €60 for LiPA-HCV genotype 
assay and €500 for sequence analysis of HCV genotype). As a 
consequence, in the analyses of actual costs, reimbursements 
from the pharmaceutical companies were not considered, as 
the local pharmacy did not receive any refund sum as of date 
(February 8, 2016). The cost-effectiveness analysis was con-
ducted considering the aforementioned direct medical costs 
and efficacy values for each patient in two scenarios: with the 
use of sequence analysis of HCV genotype vs use of LiPA-
HCV genotype assay. The time horizon considered was up to 
12 weeks after HCV antiviral therapy conclusion.
To test the robustness of the results, a resampling boot-
strapping analysis was performed, simulating 500 cohorts 
of 134 patients, randomly extracting patients from the base 
case scenario.
Ethics
The local Health Administrative Board in Chieti-Pescara 
reviewed in detail the study design, set up by the Infectious 
Diseases Staff at Pescara General Hospital. The study was thor-
oughly discussed by the Direzione Generale Strategica della 
Azienda Unità Sanitaria Locale di Pescara/Comitato Etico di 
Chieti/Pescara. A final authorization was granted by Direzione 
Generale Strategica della Azienda Unità Sanitaria Locale di 
Pescara early in 2015, as documented in issue Deliberazione 
del Direttore Generale number 319 March 16, 2015. Written 
informed consent was obtained from all participants.
Results
During the study period, 134 consecutive patients were 
included. Starting from January 2008, routine genotype and 
subtype assays were performed by Versant HCV Genotype 
2.0. Sequencing yielded discordant or complementary infor-
mation in 21 (15.7%) cases. Among these, we found three 
(2.3%) discordant genotypes, nine (6.7%) discordant G1 
subtypes, four (3%) mixed infections, and five (3.7%) indeter-
minate G1 subtypes that were then correctly attributed. Sub-
optimal treatment choice due to wrong genotype assessment 
in the three individual cases would have caused a reduction 
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. in efficacy which we gauged at our best, based on literature 
data, as ranging between 17% and 40% (Table 1). G1a was 
assigned by sequencing instead of G1b by commercial assays 
in eight out of nine cases with incorrect G1 subtype. This 
would have caused suboptimal treatment courses, with an 
expected decrease in efficacy from 5% to 7%. Conversely, 
in the single opposite case (G1b assignment instead of G1a), 
the consequence would have been a slight increase in costs 
and the requirement of ribavirin use (Table 2). For patients 
with G1 and indeterminate subtype, the choice of regimens 
would have targeted the subtype 1a option, with a potential 
sensible increase in costs (Table 2). Finally, the possible 
 consequences of inappropriate prescription due to mixed 
HCV infections are shown in Table 3. In these cases, pan-
genotypic regimens would be mandatory, with an increase 
in costs up to €32,000 per treatment.
The use of sequence analysis of HCV genotype, com-
pared with LiPA-HCV genotype assay, would lead to a mean 
increase of efficacy (+1.42%) and per capita costs (+€1,280 
per patient). The results of the cost-effectiveness analysis are 
presented in Table 4.
The 2.4% of the sensitivity analysis simulations led to a 
dominance of sequence analysis of HCV genotype compared 
with LiPA-HCV genotype assay, reducing costs and increas-
ing efficacy, while the remaining 97.6% of the results showed 
an increase in costs and efficacy (between €1,269 and €4,617, 
and 1.43% and 3.88%) with incremental cost-effectiveness 
ratios between €845/efficacy unit and €2,009/efficacy unit.
Discussion
Although some studies found uninterpretable or indeterminate 
genotype assignations in varying  percentages of assayed 
samples, especially in non-G1 HCV infections,4,12–16 the pos-
sible consequences of HCV genotype misclassification on 
treatments with DAAs were not yet evaluated and may have 
been perceived as a minor problem so far. However, in the new 
scenario of HCV therapy, the costs of genotyping by sequenc-
ing are definitely lower than those of DAA regimens, so that 
even a few treatment failures averted may make reassessing 
HCV genotype before DAAs very convenient.2 As a conse-
quence, studies aimed at gauging the improvement of treatment 
outcomes by the systematic deployment of sequence genotype 
should be encouraged. We introduced mandatory sequencing 
assays of HCV prior to HCV therapy with DAAs at our site, 
and compared the results of all consecutive assays performed 
with previous routine genotype assessments, in an attempt to 
pinpoint all possible differences in treatment efficacy and on 
possible parallel cost savings obtained in this way. Although 
 
Cl
in
ico
Ec
on
om
ics
 a
nd
 O
ut
co
m
es
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
14
9.
19
2.
11
0 
on
 2
2-
M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ClinicoEconomics and Outcomes Research 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
470
Polilli et al
T
ab
le
 2
 C
on
se
qu
en
ce
s 
on
 p
re
sc
ri
pt
io
n 
of
 in
te
rf
er
on
-fr
ee
 t
re
at
m
en
t 
re
gi
m
en
s 
in
 c
as
e 
of
 in
ac
cu
ra
te
 H
C
V
 g
en
ot
yp
e 
1 
su
bt
yp
e 
as
si
gn
m
en
t
P
at
ie
nt
M
E
T
A
V
IR
 
sc
or
e
V
er
sa
nt
 H
C
V
 
G
en
ot
yp
e 
2.
0 
ge
no
ty
pi
ng
 a
ss
ay
C
os
t-
ef
fe
ct
iv
e 
tr
ea
tm
en
t 
ba
se
d 
on
 
V
er
sa
nt
 H
C
V
 G
en
ot
yp
e 
2.
0 
as
sa
y*
Se
qu
en
ce
 
re
su
lt
s
C
os
t-
ef
fe
ct
iv
e 
tr
ea
tm
en
t 
 
ba
se
d 
on
 s
eq
ue
nc
e 
an
al
ys
is
E
st
im
at
ed
 e
ffi
ca
cy
 o
f 
tr
ea
tm
en
ts
 p
re
sc
ri
b
ed
 o
n
 
th
e 
ba
si
s 
of
 V
er
sa
nt
 H
C
V
 G
en
ot
yp
e 
2.
0 
as
sa
ys
 v
s 
tr
ea
tm
en
ts
 p
re
sc
ri
be
d 
on
 s
eq
ue
nc
e 
an
al
ys
is
 r
es
ul
ts
SO
F 
LD
V
P
T
V
 O
M
B
/R
tv
 
D
A
S
1
F3
1
N
A
12
 w
k 
w
ith
 R
BV
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
N
o 
di
ffe
re
nc
e
€
23
.9
03
€
23
,9
03
2
F3
1
N
A
12
 w
k 
w
ith
 R
BV
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
N
o 
di
ffe
re
nc
e
€
23
.9
03
€
23
,9
03
3
F3
1
N
A
12
 w
k 
w
ith
 R
BV
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
N
o 
di
ffe
re
nc
e
€
23
.9
03
€
23
,9
03
4
F4
1
24
 w
k 
or
 1
2w
 w
ith
 R
BV
N
A
1b
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
Eq
ui
va
le
nt
 e
ffi
ca
cy
 b
ut
 m
or
e 
co
st
ly
 b
y 
€
17
,7
00
€
81
,4
00
 o
r 
€
41
,6
03
€
23
,9
03
 
5
F4
1
24
 w
k 
or
 1
2w
 w
ith
 R
BV
N
A
1b
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
Eq
ui
va
le
nt
 e
ffi
ca
cy
 b
ut
 m
or
e 
co
st
ly
 b
y 
€
17
,7
00
 
€
81
,4
00
 o
r 
€
41
,6
03
 
€
23
,9
03
 
6
F4
1b
N
A
12
 w
k 
w
ith
 R
BV
1a
24
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
 R
BV
88
.6
%
 v
s 
94
.2
%
23
 
€
23
,9
03
 
€
47
,8
06
 
7
F4
1b
N
A
12
 w
k 
w
ith
 R
BV
1a
24
 w
k 
 P
T
V
 O
M
B/
R
tv
 D
A
S 
R
BV
88
.6
%
 v
s 
94
.2
%
23
€
23
,9
03
 
€
47
,8
06
 
8
F4
1b
N
A
12
 w
k 
w
ith
 R
BV
1a
24
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
 R
BV
88
.6
%
 v
s 
94
.2
%
23
€
23
,9
03
 
€
47
,8
06
9
F3
1b
N
A
12
 w
k
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
90
.2
%
 v
s 
97
%
24
€
23
,0
00
 
€
23
,9
03
 
10
F3
1b
N
A
12
 w
k
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
  D
A
S 
R
BV
90
.2
%
 v
s 
97
%
24
€
23
,0
00
 
€
23
,9
03
 
11
F2
1b
N
A
12
 w
k
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
90
.2
%
 v
s 
97
%
24
€
23
,0
00
 
€
23
,9
03
12
F3
1b
N
A
12
 w
k
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
90
.2
 v
s 
97
%
24
€
23
,0
00
€
23
,9
03
13
F1
1b
N
A
12
 w
k
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
90
.2
%
 v
s 
97
%
24
€
23
,0
00
€
23
,9
03
14
F3
1a
N
A
12
 w
k 
w
ith
 R
BV
1b
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S
Eq
ui
va
le
nt
 e
ffi
ca
cy
 b
ut
 m
or
e 
co
st
ly
 b
y 
€
90
3
€
23
,9
03
€
23
,0
00
N
ot
es
: *
T
he
 m
os
t 
lik
el
y 
pr
es
cr
ip
tio
n 
ba
se
d 
on
 r
ei
m
bu
rs
em
en
t 
al
lo
w
an
ce
 r
ul
es
 a
t 
A
IF
A
 w
eb
si
te
.
A
bb
re
vi
at
io
ns
: A
IF
A
, I
ta
lia
n 
R
eg
ul
at
or
y 
A
ge
nc
y;
 D
C
V
, d
ac
la
ta
sv
ir
; D
A
S,
 d
as
ab
uv
ir
; H
C
V
, h
ep
at
iti
s 
C
 v
ir
us
; L
D
V
, l
ed
ip
as
vi
r;
 N
A
, n
ot
 a
pp
lic
ab
le
; O
M
B,
 o
m
bi
ta
sv
ir
; P
T
V
, p
ar
ita
pr
ev
ir
; R
BV
, r
ib
av
ir
in
; R
tv
, r
ito
na
vi
r;
 S
O
F,
 s
of
os
bu
vi
r;
 w
k,
 w
ee
ks
.
 
Cl
in
ico
Ec
on
om
ics
 a
nd
 O
ut
co
m
es
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
14
9.
19
2.
11
0 
on
 2
2-
M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ClinicoEconomics and Outcomes Research 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
471
Cost-effectiveness of re-evaluating HCV genotype
T
ab
le
 3
 C
on
se
qu
en
ce
s 
on
 p
re
sc
ri
pt
io
n 
of
 in
te
rf
er
on
-fr
ee
 t
re
at
m
en
t 
re
gi
m
en
s 
in
 c
as
e 
of
 m
ix
ed
 in
fe
ct
io
ns
 b
y 
ro
ut
in
e 
H
C
V
 g
en
ot
yp
in
g
P
at
ie
nt
M
E
T
A
V
IR
sc
or
e
V
er
sa
nt
 H
C
V
 
G
en
ot
yp
e 
2.
0 
ge
no
ty
pi
ng
 a
ss
ay
a
C
os
t-
ef
fe
ct
iv
e 
tr
ea
tm
en
t 
ba
se
d 
on
 
V
er
sa
nt
 H
C
V
 G
en
ot
yp
e 
2.
0 
as
sa
ys
b
Se
qu
en
ce
 
re
su
lt
s
C
os
t-
ef
fe
ct
iv
e 
tr
ea
tm
en
t 
 
ba
se
d 
on
 s
eq
ue
nc
e 
an
al
ys
is
E
st
im
at
ed
 e
ffi
ca
cy
 o
f 
tr
ea
tm
en
ts
 p
re
sc
ri
b
ed
 o
n
 
th
e 
ba
si
s 
of
 V
er
sa
nt
 H
C
V
 G
en
ot
yp
e 
2.
0 
as
sa
ys
 v
s 
tr
ea
tm
en
ts
 p
re
sc
ri
be
d 
on
 s
eq
ue
nc
e 
an
al
ys
is
 r
es
ul
ts
1
F2
1a
/1
b
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
€
23
,9
03
1a
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S 
R
BV
€
23
,9
03
N
o 
di
ffe
re
nc
e
2
F2
1/
3/
4
12
 w
k 
SO
F 
D
C
V
€
54
,0
00
4d
12
 w
k 
PT
V
 O
M
B/
R
tv
 w
ith
 R
BV
 
€
22
,0
63
Eq
ui
va
le
nt
 e
ffi
ca
cy
 b
ut
 m
or
e 
co
st
ly
 b
y 
€
31
,9
37
3
F2
1/
4
12
 w
k 
SO
F 
LD
V
€
40
,7
00
1b
12
 w
k 
PT
V
 O
M
B/
R
tv
 D
A
S
€
23
,0
00
Eq
ui
va
le
nt
 e
ffi
ca
cy
 b
ut
 m
or
e 
co
st
ly
 b
y 
€
17
,7
00
4
F4
1b
/3
24
 w
k 
SO
F 
D
C
V
 R
BV
€
10
9,
80
6
3a
24
 w
k 
SO
F 
D
C
V
 R
BV
€
10
9,
80
6
N
o 
di
ffe
re
nc
e
N
ot
es
: a
So
m
e 
pa
tie
nt
s 
ha
d 
tw
o 
or
 t
hr
ee
 r
es
ul
ts
 a
t 
th
ei
r 
pr
ec
ed
in
g 
as
sa
y.
 b T
he
 m
os
t 
lik
el
y 
pr
es
cr
ip
tio
n 
ba
se
d 
on
 r
ei
m
bu
rs
em
en
t 
al
lo
w
an
ce
 r
ul
es
 a
t 
A
IF
A
 w
eb
si
te
. S
om
e 
pa
tie
nt
s 
ha
d 
tw
o 
or
 t
hr
ee
 r
es
ul
ts
  a
t 
th
ei
r 
pr
ec
ed
in
g 
as
sa
y.
A
bb
re
vi
at
io
ns
: A
IF
A
, I
ta
lia
n 
R
eg
ul
at
or
y 
A
ge
nc
y;
 D
C
V
, d
ac
la
ta
sv
ir
; D
A
S,
 d
as
ab
uv
ir
; H
C
V
, h
ep
at
iti
s 
C
 v
ir
us
; L
D
V
, l
ed
ip
as
vi
r;
 O
M
B,
 o
m
bi
ta
sv
ir
; P
T
V
, p
ar
ita
pr
ev
ir
; R
BV
, r
ib
av
ir
in
; R
tv
, r
ito
na
vi
r;
 S
O
F,
 s
of
os
bu
vi
r;
 w
k,
 w
ee
ks
.
based at a single Italian site among the many authorized for 
the prescription of new treatments for HCV, one major strength 
of our experimental design was the consecutive enrolment to 
sequence genotyping of all DAA eligible patients. This allowed 
a close estimate of the benefits of this investigational procedure 
in a relatively small sample of treated patients.
We found percentages of HCV genotype/subtype misclas-
sification approximately in line with those reported by oth-
ers,3,13,16–18 identifying four main groups of failures in routine 
genotyping. In the first group, we included three patients with 
misclassified genotypes. These would have had the potential 
of causing remarkable reductions in efficacy – up to 40% – of 
their respective DAA treatments, which means a high likeli-
hood of inducing at least one treatment failure. This first group 
alone justified our effort and covered all study expenses. In the 
second and third groups were included several cases of inde-
terminate subtype or subtype misclassification. These would 
not have caused a significant reduction in efficacy; however, 
significant increases in costs would have occurred, especially 
for patients receiving a diagnosis of genotype 1a instead of 
1b, and unduly longer and more toxic treatments. In these 
patients, the reduction in potential toxicity was an added and 
precious value on the top of averted expenses. In the last group 
of patients, mixed infections would have invariably induced the 
prescription of pan-genotypic regimens, causing a remarkable 
increase in costs, at least 50% greater than necessary.
The cost-effectiveness results show an overall increase 
in terms of efficacy due to the use of sequence analysis of 
HCV genotype along with a slight increase in terms of costs. 
The cost per unit of efficacy gained is difficult to interpret 
due to the lack of threshold values associated with SVR at 
12 weeks for HCV-infected patients.
The analysis performed does not consider the savings due 
to the mean efficacy increase and the need of further antiviral 
treatments and monitoring for patients not reaching SVR in 
the LiPA-HCV genotype assay scenario. Moreover, adverse 
events–related costs were not considered in the analysis 
due to the absence of interferon in the antiviral treatments 
considered (assuming similar safety profiles), which would, 
however, increase the direct medical costs due to retreat-
ments. Further cost savings not considered in the analysis 
due to higher efficacy of treatments are those related to the 
lack of progression of HCV infection.
Future analyses should include a measurement of moni-
toring activities, adverse events management, and follow-up.
The main limit of the cost-effectiveness analysis per-
formed is related to the short-term time horizon and the lack 
of use of effectiveness parameters that allow to interpret incre-
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mental cost-effectiveness ratio of technology use based on 
national recognized thresholds (ie, quality adjusted life years).
Overall, our experience highlights the importance and 
convenience of accurate HCV genotyping before current 
DAA regimens. If wrong or incomplete, HCV genotype 
information would have caused a preventable risk of treat-
ment failure. The relatively low incremental costs of HCV 
sequence analysis compared with the current costs of DAAs 
suggests that precise assignation of HCV genotype and 
subtype by sequencing may be beneficial until new and 
more potent pan-genotypic regimens will be available for all 
patients. Therefore, for a personalized and tailored therapy, 
genotype by sequencing should be performed in advance of 
first-line treatment with DAAs.
Conclusion
Further analyses on the cohort, considering a longer time 
horizon, should investigate if, as potentially suggested by the 
results of the analysis presented, the use of sequence analysis 
of HCV genotype would lead to a decrease in direct medical 
costs for the treatment of HCV-infected patients, due to sav-
ings for the lower number of retreated patients and lack of 
disease progression. Further research is warranted.
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Table 4 Results of cost-effectiveness analysis
Scenario Mean cost (€) Mean incremental 
cost (€)
Mean efficacy (%) Mean incremental 
efficacy (%)
Incremental cost-
effectiveness ratio 
LiPA-HCV genotype assay 41,338 NA 94.98 NA NA
HCV genotype sequencing 42,618 +1,280 96.40 +1.42 899.6
Abbreviations: HCV, hepatitis C virus; NA, not applicable.
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